Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis

Overview

This is a multicenter, randomized, double-blind, double-dummy, active-controlled, dose-finding study to compare the efficacy, safety and tolerability of oral SCY-078 versus oral fluconazole in adult female subjects 18 years and older with moderate to severe Acute Vulvovaginal Candidiasis (AVVC). Approximately 180 eligible subjects (30 subjects per treatment group) will be enrolled and randomized into the study.

Full Title of Study: “A Phase 2, Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled, Dose-Finding Study to Compare the Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis”

Study Type

• Study Type: Interventional
• Study Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Primary Purpose: Treatment
  • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Study Primary Completion Date: May 4, 2018

Detailed Description

This is a Phase 2, multicenter, randomized, double-blind, double-dummy, active-controlled, dose-ranging study of female subjects with moderate to severe Acute Vulvovaginal Candidiasis. Subjects will be randomized to either the investigational arm (SCY-078) with 5 different dose regiments ranging from 1 to 3 days of treatment or to the active-control arm (fluconazole) for 1 day of treatment. After randomization subjects may be seen on study Day 3 (on site visit for PK subjects) , Day 10 (±2,) and Day 25 (+4).

Interventions

• Drug: Fluconazole
  • Oral Antifungal comparator
• Drug: SCY-078
  • Investigational Antifungal

Arms, Groups and Cohorts

• Active Comparator: Fluconazole
  • 150 mg/day for 1 day
• Experimental: Ibrexafungerp 750mg
  • 750mg QD for 1 day only
• Experimental: Ibrexafungerp 300mg
  • 300mg BID for 1 day only
• Experimental: Ibrexafungerp 450mg
  • 450mg BID for 1 day only
• Experimental: Ibrexafungerp 150mg
  • 150mg BID for 3 days
• Experimental: Ibrexafungerp 300mg D1-D3
  • 300mg BID for 3 days

Clinical Trial Outcome Measures

Primary Measures

• Clinical Cure (Complete Resolution of Signs and Symptoms)
  • Time Frame: 8-12 days
  • Measured by the percentage of subjects with clinical cure (complete resolution of signs and symptoms) at the test-of-cure (TOC) visit

Secondary Measures

• Co-occurrence of Clinical and Mycological Cure
  • Time Frame: 29 days
  • The percentage of subjects with both clinical cure and mycological eradication (negative fungal culture) the Test-of cure.

Participating in This Clinical Trial

Key Inclusion Criteria:

1. Subject is a female of at least 18 years of age 2. Subject has a diagnosis of symptomatic AVVC at baseline including a positive microscopic examination with 10% KOH in a vaginal sample revealing yeast forms (hyphae/pseudohyphae) or budding yeasts, and vaginal pH (≤4.5) Key Exclusion Criteria:

1. Subject has any vaginal condition other than AVVC that may interfere with the diagnosis or evaluation of response to therapy, such as suspected or confirmed concurrent causes of vulvovaginitis and/or cervicitis (mixed infection) 2. Need for systemic and/or topical (vaginal) antifungal treatment, including prescription or over-the-counter products during the study and treatment for VVC 28 days prior to randomization 3. Subject is actively menstruating at the time of the Baseline visit. 4. Subject has uncontrolled diabetes mellitus. 5. Subject has a vaginal sample with pH >4.5. 6. Subject has a history of or an active cervical/vaginal cancer.

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

• Lead Sponsor
  • Scynexis, Inc.
• Provider of Information About this Clinical Study
  • Sponsor
• Overall Official(s)
  • David Angulo, MD, Study Director, Scynexis, Inc.